Skip to main content
SK Bioscience Co.,Ltd logo

SK Bioscience Co.,Ltd — Investor Relations & Filings

Ticker · 302440 ISIN · KR7302440003 KO Manufacturing
Open in API
Filings indexed 381 across all filing types
Latest filing 2025-06-25 M&A Activity
Country KR South Korea
Listing KO 302440

About SK Bioscience Co.,Ltd

https://www.skbioscience.com/

SK Bioscience is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines and biological products. Spun off from SK Chemicals in 2018, the company develops its own pipeline of vaccines, including cell-culture-based influenza vaccines and a COVID-19 vaccine, utilizing its established R&D and production platforms. In addition to its proprietary products, SK Bioscience provides global Contract Development and Manufacturing Organization (CDMO) services, offering end-to-end support from process development to large-scale commercial manufacturing for international partners. The company is dedicated to promoting public health by providing innovative preventative solutions to address global health challenges.

Recent filings

Filing Released Lang Actions
[기재정정]타법인주식및출자증권취득결정(종속회사의주요경영사항)
M&A Activity Classification · 1% confidence The document is a regulatory filing from SK Bioscience regarding an amendment to a previous announcement about the acquisition of shares in another company (IDT Biologika GmbH). It details the correction of acquisition amounts and provides updated financial information related to the transaction. As this is a formal regulatory disclosure of a corporate action (M&A/Investment) filed with the exchange, it falls under the category of Regulatory Filings.
2025-06-25 Korean
[기재정정]투자판단관련주요경영사항 (21가 폐렴구균백신(GBP410)의 미국 제3상 임상시험계획 (IND) 승인)
Legal Proceedings Report Classification · 1% confidence The document is a regulatory filing from SK Bioscience regarding the approval of a Phase 3 clinical trial (IND) for their 21-valent pneumococcal vaccine (GBP410) by the US FDA. It is a 'Major Management Matter' (투자판단 관련 주요경영사항) filing, which is a standard regulatory disclosure in the Korean market (KRX) for significant corporate developments. Since it does not fit into specific categories like financial reports, dividends, or M&A, and is a formal regulatory disclosure of a material event, it is classified as a Regulatory Filing (RNS).
2025-06-09 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 1% confidence The document is a regulatory disclosure from SK Bioscience regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) with the Public Procurement Service of South Korea. It details the contract value, duration, and terms. Since this is a specific regulatory announcement of a material business contract that does not fit into categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2025-06-04 Korean
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
Major Shareholding Notification Classification · 1% confidence The document is a 'Corporate Group Status Disclosure' (기업집단현황공시) for SK Bioscience, which is a mandatory regulatory filing in South Korea under the Fair Trade Commission's regulations for large business groups. It contains detailed information on company structure, financial status, board composition, shareholding, and inter-company transactions. Since it is a formal regulatory disclosure required by law and does not fit into specific categories like 10-K or Earnings Release, it is classified as a Regulatory Filing (RNS).
2025-05-30 Korean
기업지배구조보고서공시
Governance Information Classification · 1% confidence The document is a 'Corporate Governance Report' (기업지배구조보고서) for SK Bioscience. It details the company's governance structure, board composition, shareholder rights, and internal control policies. In the context of Korean regulatory filings (DART), this document is a specific annual disclosure requirement regarding corporate governance practices, which falls under the 'Governance Information' category.
2025-05-30 Korean
분기보고서 (2025.03)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for SK Bioscience, covering the period from 2025.01.01 to 2025.03.31. It contains detailed financial and operational information, including business overview, product status, production capacity, and financial risk management. It is a comprehensive report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-14 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.